A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 285: 879–886.

Published: 18th February 2014

Authors: Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M et al. et al.


In this study that included 74 patients who had complete resection of recurrent colorectal cancer treated with one of two immunisations, median recurrence-free survival at two years was 47 and 55 per cent in the two groups, an improvement compared with the survival rate of a contemporary groups of patients who were not vaccinated.

Pubmed Link

Your comments